Small changes to healthy cells can sometimes lead to cancer. In almost every case of pancreatic cancer, one of those changes is a mutation in the gene KRAS, including pancreatic ductal adenocarcinoma (PDA), a highly aggressive type of pancreatic cancer. The genetic landscape of PDA based on KRAS status is not well studied. Investigators from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, investigated genomic alterations based on KRAS status to identify mutations in patients with KRAS wild type (WT). Read more at cinj.org.
Matthew Pierre Deek, MD, radiation oncologist at Rutgers Cancer Institute and assistant professor of radiation oncology at Rutgers Robert Wood Johnson Medical School